Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer

Breast Cancer Research and Treatment

Volumn 126, Issue 1, 2011, Pages 93-99

  Kim, Eun Kyu ^a   Kim, Hyun Ah ^a   Koh, Jae Soo ^a   Kim, Min Suk ^b   Kim, Kwan Il ^a   Lee, Jong Inn ^a   Moon, Nan Mo ^b   Ko, Eunyoung ^b   Noh, Woo Chul ^a  

^a Korea Cancer Center Hospital   (South Korea)

^b Dongnam Institute of Radiological and Medical Science   (South Korea)

Author keywords

Breast cancer; Endocrine therapy resistance; Hormone receptor; P S6K1; Prognosis

Indexed keywords

AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; PROGESTERONE RECEPTOR; RAPAMYCIN; S6 KINASE; S6 KINASE 1; TAMOXIFEN; TOREMIFENE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE OVEREXPRESSION; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM STAGING; PHOSPHORYLATION; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79151470770     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1315-z     Document Type: Article

References (29)

1. RJ Shaw LC Cantley 2006 Ras, PI(3)K and mTOR signalling controls tumour cell growth Nature 441 424 430 10.1038/nature04869 1:CAS:528: DC%2BD28XkvVyrsr8%3D 10.1038/nature04869 16724053 (Pubitemid 44050136)
2. F Meric-Bernstam AM Gonzalez-Angulo 2009 Targeting the mTOR signaling network for cancer therapy J Clin Oncol 27 2278 2287 10.1200/JCO.2008.20.0766 1:CAS:528:DC%2BD1MXlvFOgs7k%3D 10.1200/JCO.2008.20.0766 19332717
3. RL Dillon DE White WJ Muller 2007 The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer Oncogene 26 1338 1345 10.1038/sj.onc.1210202 1:CAS:528:DC%2BD2sXitVKhs7Y%3D 10.1038/sj.onc.1210202 17322919 (Pubitemid 46328463)
4. AS Strimpakos EM Karapanagiotou MW Saif KN Syrigos 2009 The role of mTOR in the management of solid tumors: an overview Cancer Treat Rev 35 148 159 10.1016/j.ctrv.2008.09.006 1:CAS:528:DC%2BD1MXivVWiu7w%3D 10.1016/j.ctrv.2008. 09.006 19013721
5. N Hay N Sonenberg 2004 Upstream and downstream of mTOR Genes Dev 18 1926 1945 10.1101/gad.1212704 1:CAS:528:DC%2BD2cXmvFKqsLk%3D 10.1101/gad.1212704 15314020 (Pubitemid 39071573)
6. EK Rowinsky 2004 Targeting the molecular target of rapamycin (mTOR) Curr Opin Oncol 16 564 575 1:CAS:528:DC%2BD2cXhtVOqt7bN 10.1097/01.cco.0000143964. 74936.d1 15627018 (Pubitemid 39482975)
7. WC Noh WH Mondesire J Peng W Jian H Zhang J Dong GB Mills MC Hung F Meric-Bernstam 2004 Determinants of rapamycin sensitivity in breast cancer cells Clin Cancer Res 10 1013 1023 1:CAS:528:DC%2BD2cXhtFCgurY%3D 10.1158/1078-0432.CCR-03-0043 14871980 (Pubitemid 38198903)
8. S Vignot S Faivre D Aguirre E Raymond 2005 mTOR-targeted therapy of cancer with rapamycin derivatives Ann Oncol 16 525 537 10.1093/annonc/mdi113 1:STN:280:DC%2BD2M7kvVWmsQ%3D%3D 10.1093/annonc/mdi113 15728109 (Pubitemid 40613318)
9. JE Dancey 2006 Therapeutic targets: MTOR and related pathways Cancer Biol Ther 5 1065 1073 1:CAS:528:DC%2BD2sXktlejsQ%3D%3D 16969122
10. M Barlund F Forozan J Kononen L Bubendorf Y Chen ML Bittner J Torhorst P Haas C Bucher G Sauter OP Kallioniemi A Kallioniemi 2000 Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis J Natl Cancer Inst 92 1252 1259 1:CAS:528:DC%2BD3cXlvFyhsb0%3D 10.1093/jnci/92.15.1252 10922410 (Pubitemid 30627733)
11. JA van der Hage LJ van den Broek C Legrand PC Clahsen CJ Bosch EC Robanus-Maandag CJ van de Velde MJ van de Vijver 2004 Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients Br J Cancer 90 1543 1550 10.1038/sj.bjc.6601741 10.1038/sj.bjc.6601741 15083183 (Pubitemid 38648236)
12. G Perez-Tenorio O Stal 2002 Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients Br J Cancer 86 540 545 10.1038/sj.bjc.6600126 1:CAS:528:DC%2BD38XislCmtro%3D 10.1038/sj.bjc.6600126 11870534 (Pubitemid 34185089)
13. GE Stoica TF Franke A Wellstein E Morgan F Czubayko HJ List R Reiter MB Martin A Stoica 2003 Heregulin-beta1 regulates the estrogen receptor-alpha gene expression and activity via the ErbB2/PI 3-K/Akt pathway Oncogene 22 2073 2087 10.1038/sj.onc.1206311 1:CAS:528:DC%2BD3sXislyiurw%3D 10.1038/sj.onc.1206311 12687010 (Pubitemid 36539558)
14. O Stal G Perez-Tenorio L Akerberg B Olsson B Nordenskjold L Skoog LE Rutqvist 2003 Akt kinases in breast cancer and the results of adjuvant therapy Breast Cancer Res 5 R37 R44 1:CAS:528:DC%2BD3sXjtlegtL0%3D 10.1186/bcr569 12631397
15. E Tokunaga A Kataoka Y Kimura E Oki K Mashino K Nishida T Koga M Morita Y Kakeji H Baba S Ohno Y Maehara 2006 The association between Akt activation and resistance to hormone therapy in metastatic breast cancer Eur J Cancer 42 629 635 10.1016/j.ejca.2005.11.025 1:CAS:528:DC%2BD28Xit1Citbc%3D 10.1016/j.ejca.2005.11.025 16464571 (Pubitemid 43343685)
16. LWC Chow Y Sun J Jassem J Baselga DF Hayes AC Wolff S Hachemi M Cincotta BW Yu S Kong L Moore 2006 Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer [abstract] Breast Cancer Res Treat 100 suppl 1 6091
17. WC Noh YH Kim MS Kim JS Koh HA Kim NM Moon NS Paik 2008 Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables Breast Cancer Res Treat 110 477 483 10.1007/s10549-007-9746-x 1:CAS:528:DC%2BD1cXosVOgtL4%3D 10.1007/s10549-007- 9746-x 17805960 (Pubitemid 351962593)
18. DC Allred MA Bustamante CO Daniel HV Gaskill AB Cruz Jr 1990 Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance Arch Surg 125 107 113 1:STN:280:DyaK3c7gtlymtQ%3D%3D 1688490
19. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717 10.1016/S0140-6736(05)66544-0 10.1016/S0140-6736(05)66544-0 (Pubitemid 40719106)
20. EA Musgrove RL Sutherland 2009 Biological determinants of endocrine resistance in breast cancer Nat Rev Cancer 9 631 643 10.1038/nrc2713 1:CAS:528:DC%2BD1MXhtVegtrzL 10.1038/nrc2713 19701242
21. RA McClelland D Barrow TA Madden CM Dutkowski J Pamment JM Knowlden JM Gee RI Nicholson 2001 Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182, 780 (Faslodex) Endocrinology 142 2776 2788 1:CAS:528:DC%2BD3MXkslels7o%3D 10.1210/en.142.7.2776 11415996 (Pubitemid 32575512)
22. JM Knowlden IR Hutcheson HE Jones T Madden JM Gee ME Harper D Barrow AE Wakeling RI Nicholson 2003 Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells Endocrinology 144 1032 1044 1:CAS:528: DC%2BD3sXhslCqtro%3D 10.1210/en.2002-220620 12586780 (Pubitemid 36262870)
23. IR Hutcheson JM Knowlden TA Madden D Barrow JM Gee AE Wakeling RI Nicholson 2003 Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells Breast Cancer Res Treat 81 81 93 10.1023/A:1025484908380 1:CAS:528:DC%2BD3sXms1Gjs7o%3D 10.1023/A:1025484908380 14531500 (Pubitemid 37108443)
24. JM Peralba L DeGraffenried W Friedrichs L Fulcher V Grunwald G Weiss M Hidalgo 2003 Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients Clin Cancer Res 9 2887 2892 1:CAS:528:DC%2BD3sXmtF2iu74%3D 12912932 (Pubitemid 36993245)
25. E Galanis JC Buckner MJ Maurer JI Kreisberg K Ballman J Boni JM Peralba RB Jenkins SR Dakhil RF Morton KA Jaeckle BW Scheithauer J Dancey M Hidalgo DJ Walsh 2005 Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study J Clin Oncol 23 5294 5304 10.1200/JCO.2005.23.622 1:CAS:528:DC%2BD2MXpslOrtLw%3D 10.1200/JCO.2005.23. 622 15998902 (Pubitemid 46206983)
26. AM Gonzalez-Angulo F Meric-Bernstam 2010 Metformin: a therapeutic opportunity in breast cancer Clin Cancer Res 16 1695 1700 10.1158/1078-0432.CCR- 09-1805 1:CAS:528:DC%2BC3cXjtFyhtLk%3D 10.1158/1078-0432.CCR-09-1805 20215559
27. LM Berstein W Yue JP Wang RJ Santen 2010 Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells Breast Cancer Res Treat 10.1007/s10549-010-1072-z 20683653
28. KE O'Reilly F Rojo QB She D Solit GB Mills D Smith H Lane F Hofmann DJ Hicklin DL Ludwig J Baselga N Rosen 2006 mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res 66 1500 1508 10.1158/0008-5472.CAN-05-2925 10.1158/0008-5472.CAN-05-2925 16452206 (Pubitemid 43259931)
29. M Zakikhani MJ Blouin E Piura MN Pollak 2010 Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells Breast Cancer Res Treat 123 271 279 10.1007/s10549-010-0763-9 1:CAS:528:DC%2BC3cXoslekt7k%3D 10.1007/s10549-010-0763-9 20135346